Bionoid Pharma, Inc. Announces Completion of 2022 and 2023 Financial Audits by PCAOB-Registered Firm
-
As Venezuela quake deaths pass 3,000, attention turns to mourning, burials
-
Gotterup wins PGA John Deere after Kohles splashdown
-
FIFA clear US star Balogun to play in World Cup after Trump call
-
Haaland knocks Brazil out of World Cup as Norway reach quarters
-
Gauff downs Bencic to book maiden Wimbledon quarter-final
-
'Catastrophic' Super Typhoon Bavi hits US island of Rota
-
Spain boss backs Yamal to sparkle in Portugal World Cup showdown
-
West Indies trail Sri Lanka by 231 runs
-
Australia's World Cup final win vindicates Molineux's self-belief
-
FIFA clear US star Balogun to play after Trump call
-
Sinner powers into fifth straight Wimbledon quarter-final
-
Venezuela quake survivor 'reborn' after eight days in rubble
-
Euphoric homecoming for Cape Verde after heroic World Cup run ends
-
Red-card U-turn rocks World Cup as England face Azteca test
-
White supremacist march in DC just 'messy' democracy, official says
-
Struff oldest first-time men's Slam quarter-finalist in Open era
-
'Perfectionist' Djokovic not happy to win ugly at Wimbledon
-
Banana!: 'Minions' knocks 'Toy Story' off N.America box office perch
-
'Catastrophic' Super Typhoon Bavi aims at US Pacific island Rota
-
Sabalenka wants to drink, 'forget about tennis' after Wimbledon exit
-
Reflective Ronaldo takes on critics 'trying to kill me for 23 years'
-
Mooney stars as Australia hammer England in women's World Cup final
-
Verstappen claims Red Bull car 'dangerous' after crash
-
Djokovic makes history, Osaka sends Sabalenka crashing out of Wimbledon
-
Trump thanks FIFA for suspending USA's Balogun World Cup ban
-
Osaka beats world number one Sabalenka in Wimbledon last 16
-
Mooney stars as Australia hammer England in women's T20 World Cup final
-
Eala eyeing Wimbledon quarters, Dimitrov faces Fery
-
Russell concedes Ferrari are threat to Mercedes
-
'Privileged' Del Toro wins Tour de France stage, Pogacar up to 2nd
-
Leclerc snaps winless run to reignite title race
-
Del Toro too tired to watch Mexico World Cup clash
-
Infernos devastate forests as Europe's temperatures rise again
-
Court frees Albania protesters held after violent clashes
-
'Tough' Leclerc delivers Ferrari's 250th win with victory in British GP
-
Four-legged rescuers lead way after Venezuela quakes
-
Tour de France stage 3rd stage to go ahead despite forest fires: official
-
France show they can ditch flair and win a different way in World Cup quest
-
Spain's Rodri warns Portugal best yet to come at World Cup
-
Australia hold England to 150-4 in Women's T20 World Cup final
-
Djokovic makes Wimbledon history to reach quarter-finals
-
Leclerc delivers Ferrari's 250th win with victory in British GP
-
Del Toro wins Tour de France stage, Pogacar up to 2nd
-
White supremacist march in DC just 'messy' democracy: US official
-
Euphoric homecoming for Cape Verde after heroic World Cup defeat
-
'Country Roads' stars as unofficial US anthem at World Cup
-
Tour de France stage under threat due to forest fires: official
-
F1 boss Domenicali hopes to restore cancelled Gulf grand prix
-
UK hard-right leader Farage faces new allegations over gifts
-
Real Madrid sign Dumfries from Inter Milan
Bionoid Pharma, Inc. Announces Completion of 2022 and 2023 Financial Audits by PCAOB-Registered Firm
NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Bionoid Pharma, Inc. ("Bionoid") (OTC PINK:BINP) is pleased to announce the successful completion of its financial audits for the fiscal years 2022 and 2023 by Olayinka Oyebola & Co., a PCAOB-registered firm. This milestone marks a significant step in Bionoid's commitment to financial transparency and regulatory compliance as the company continues executing its long-term growth strategy.
Olayinka Oyebola & Co. has worked diligently to complete the audits in accordance with Public Company Accounting Oversight Board (PCAOB) standards, ensuring the accuracy and integrity of Bionoid's financial reporting. The firm remains on track to finalize the company's 2024 financial statements as scheduled, further strengthening Bionoid's financial standing.
"The completion of our 2022 and 2023 audits is a critical achievement for Bionoid and underscores our dedication to financial accountability," said Wayne Cockburn, CEO of Bionoid Pharma, Inc. "As we continue our expansion through strategic acquisitions and AI-driven growth initiatives, maintaining strong financial governance remains a top priority. We appreciate the expertise and professionalism of Olayinka Oyebola & Co. and look forward to the timely completion of our 2024 financials."
Bionoid remains focused on scaling its operations through revenue-generating e-commerce acquisitions and the integration of its AI Maverick platform, positioning the company for sustainable growth and enhanced investor confidence.
About Bionoid Pharma, Inc.
Bionoid Pharma, Inc. is a forward-thinking health and wellness company dedicated to expanding revenue streams and brand presence through strategic acquisitions and advanced AI technology. Its proprietary AI Maverick platform enhances customer engagement and operational efficiency, supporting the company's mission to deliver innovative, AI-driven solutions for long-term growth.
Stay connected:
Website: BionoidPhama.com
OTC Markets: BINP
For further information, contact:
Wayne Cockburn, CEO
Phone: (905) 505-0770
Email: [email protected]
SOURCE: Bionoid Pharma, Inc.
View the original press release on ACCESS Newswire
H.Gonzales--AT
